NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Hopeforthefuture3, I have a few questions for you. Please answer each question:

(1) Do you know that the current standard of care (SOC) to treat newly diagnosed GBM patients (surgery + Temodar + Radiation) only has a response rate of less than 5% (4.7%), and it only added about 2 months on average to OS for ndGBM patients?

(2) Do you know that the current SOC became the SOC in 2005 to treat all GBM patients, even though it only added about 2 months of OS?

(3) Do you believe it is important that DCVax-L increases the number of 1-Year, 2-Year, 3-Year, 4-Year, 5-Year, and 5+-Year survivors, for all GBM patients across the board, regardless of gene type, methylation status or any other prognostic factor?

(4) If you define a response rate as 5 or more years of overall survival, historically what percent of patients treated with the current standard of care (SOC) reach 5-Years overall survival?

I will await your responses, but here are some clues: